APP download


Tel: +86-571-89360709  E-mail:
Address: 21-23, Health Valley, No. 1500, Wenyi West Road, Yuhang District, Hangzhou, Zhejiang, China
Copyright: Hangzhou Repugene Technology Co., Ltd.   Powered by  

Hangzhou Repugene Technology Co., Ltd.  is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.

core team

Dr. Lin Rui, Director of Gene Sequencing

Release time:
2019/01/19 17:18
Page view
Doctor of Biomedical Sciences, University of Hawaii, USA
Postdoctoral fellow at the Scripps Research Institute
Has provided CRO services to many of the world's top pharmaceutical companies
Discover new tumor marker genes
Create a new high-sensitivity second-generation sequencing method
He graduated from the School of Life Sciences of Fudan University with a Ph.D. in Biomedical Sciences from the University of Hawaii and completed his postdoctoral research at the Scripps Research Institute in California.
Dr. Lin has extensive experience in the establishment of genetic sequencing methods, biomarker discovery and research, clinical trials, CRO, etc. He discovered a new gene Hepcarcin at Scripps Research; Hepcarcin and Malat-1 were found as six Evidence for potential biomarkers of solid tumors.
In the United States, Transgenomic pioneered the next-generation sequencing (NGS) technology after COLD-PCR, which established a new platform for high-throughput and high-sensitivity cancer gene mutation detection from liquid biopsy specimens and tumor tissue specimens. The NGS method of multiplex PCR was established to detect 50 oncogenes and tumor suppressor gene mutations simultaneously. The NGS method of multiplex PCR was established to detect mRNA expression of 50 oncogenes simultaneously. The method of extracting patient plasma cfDNA and real-time PCR for quantitative analysis of cfDNA was validated; this platform was used to provide a number of clinical trial CRO services for the top ten pharmaceutical companies in the world.
The published academic articles mainly include:
1 Castellanos-Rizaldos, E., Richardson K, Lin, R., et al. (2015) Single-tube, highly parallel mutation enrichment in cancer gene panels using temperature-tolerant COLD-PCR. Clin Chem 61:267-277.
2 Lin, R., Saha, MR, Black, C., Watt, A., Marcusson, E., Freier, SM, and Edgington, TS (2011) Control of RNA processing by a large non-coding RNA over-expressed In carcinomas. FEBS Letters 585:671-676.
3 Wang, Y., Kelber, JA, Tran Cao, HS, Cantin, GT, Lin, R., et al. (2010) Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression. Proceedings of National Academy of Sciences. 107: 10920-10925.
4 Lin, R., Maeda, S., Liu C., Karin, M., and Edgington, TS (2007) A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26:851- 858.
5 Lin, R., Martyn, KD, Guyette, CV, Lau, AF, and Warn-Cramer, BJ (2006) V-src-mediated tyrosine phosphorylation of connexin43: down regulation of gap junction communication and the effects on transformation. Communication and Adhesion 13: 199-216.
6 Cottrell, GT., Lin, R., Warn-Cramer, BJ, Lau, AF, and Burt, JM (2003) Mechanism of v-Src and mitogen activated protein kinase induced reduction of gap junction communication. American Journal of Physiology Cell Physiology 284: C511-C520.
7 Lin, R., Warn-Cramer, B.J., Kurata, W., and Lau, A.F. (2001) v-Src Phosphorylation of Connexin43 on Tyr247 and Tyr265 Disrupts Gap Junctional Communication. Journal of Cell Biology 154: 815-827.